Aim To evaluate the effectiveness of combined lasers with different wavelengths in creating chorioretinal venous anastomosis (CRVA) in nonischaemic central retinal vein occlusion (CRVO). Methods In this retrospective, noncomparative, consecutive case series, records of all patients with a diagnosis of nonischaemic CRVO who underwent combined laser treatment to induce CRVA and who were followed-up for 6 months or longer were reviewed. Results Records of 85 patients (85 eyes) were analysed. These patients were divided into two groups. In group 1 (24 cases, 24 eyes), combined lasers with two different wavelengths (argon blue-green laser combined with Nd-YAG laser were used. In group 2 (61 cases, 61 eyes), combined lasers with three different wavelengths (argon bluegreen laser combined with krypton red laser and Nd-YAG laser) were used. Functional anastomosis formed in 13 out of 24 eyes (54%) in group 1 and 47 out of 61 eyes (77%) in group 2. In patients with successful anastomosis, visual acuity improved for two or more lines in 49 out of 60 eyes (82%), with the remaining eyes undergoing no change. There were no serious complications. Conclusion The use of three laser wavelengths results in the creation of laser anastomosis and the success rate may be higher than when using two wavelengths alone.
Introduction
Laser-induced chorioretinal venous anastomosis (CRVA) was shown to be a new and effective treatment for retinal vein occlusion.
1,2 A high-intensity argon laser was applied to a vein and underlying or adjacent Bruch's membrane, sometimes combined with an Nd:YAG laser, to induce the anastomosis formation. But there were two problems that limited its use in the clinic: (1) the success rate of anastomosis formation was relatively low (33-54%) and (2) it was sometimes associated with serious complications. The most serious complications associated with the treatment were choroidovitreal neovascularization that may lead to vitreous haemorrhage and traction retinal detachment. [1] [2] [3] [4] [5] [6] We describe the treatment results using combined lasers with different wavelengths to induce CRVA in 85 eyes of 85 consecutive patients with nonischaemic central retinal vein occlusion (CRVO).
Patients and methods

Patients
Records of all patients with nonischaemic CRVO treated with laser-induced CRVA between 1999 March and 2004 October were reviewed retrospectively. Nonischaemic CRVO was determined to be less than 10-disc diameters of capillary nonperfusion seen on fluorescein angiography in the area corresponding to that used by the Central Vein Occlusion Study. 7 As neovascular complications were associated with retinal ischaemia, 1 we selected patients with capillary nonperfusion of less than 5-disc diameters, in order to decrease the occurrence of neovascular complications. All the patients had experienced a progressive deterioration of visual acuity for at least 1 month. Informed consent with full disclosure of the experimental nature of the treatment was obtained from all the patients. Committee Review Board approval for the treatment was obtained at the beginning of the study.
Treatments
With the use of topical anaesthesia and fundus contact lens, laser photocoagulation was applied to selected locations along a retinal vein, at least 3-disc diameters superior or nasal to the optic disc. Combined lasers with different wavelengths were used. Before 2000 February, combined lasers with two different wavelengths (argon blue-green laser combined with Nd-YAG laser) were used in all the cases. The argon blue-green laser (2-2.4 W, 50 mm, 0.1 s) was applied at the edge or on top of the vein, usually one, and occasionally two shots at each treatment site. Then the Nd-YAG laser (3-8 mj) was applied at the treatment site to break the retinal vein. From 2000 February, combined lasers with three different wavelengths (argon blue-green laser combined with krypton red laser and Nd-YAG laser) were used. At first, the argon blue-green laser (1.6-2 W, 50 mm, 0.1 s) was applied at the edge or on top of the vein, usually one, and occasionally two shots at each treatment site. Then, the krypton red laser (1 W, 50 mm, 0.1 s) was applied at the same site, usually one, and occasionally two shots at each treatment site. At last, the Nd-YAG laser (3-8 mj) was applied at the treatment site to break the retinal vein. Localized retinal haemorrhage at the treatment site could be controlled with pressure on the contact lens. All the treatments were completed by one doctor.
Scattered argon laser photocoagulation (argon green laser, 0.16-0.20 W, 500 mm, 0.2 s) was applied over the drainage area of the vein distal to the treatment sites for all the cases. Usually, 400-600 laser sports were applied.
The patients were examined 2 weeks after treatment, and then at monthly intervals until anastomosis formed. After that, the patients were followed at 3 months interval. The criterion to determine a successful anastomosis (Figures 1-3 ) was the ophthalmoscopic appearance of the central/peripheral segment of the treated vein dipping down into the choroid at the treatment site and preferential filling of the anastomotic vein at the early stage of fundus fluorescein angiography (FFA). Post-treatment fundus photographs and FFA were obtained. During follow-up, progression of nonischaemic CRVO to the ischaemic type was defined by the The w 2 test was used to determine whether the proportions of a single group divided into two categories were significantly different, with a significance acceptance level of Po0.05. All mean data are expressed as a mean7SD.
Results
A total of 85 patients (85 eyes) with nonischaemic CRVO received the treatments (Table 1) . Ages varied from 18 to 70 years, with an average7SD of 51.0712.2. Patients who received the argon blue-green laser combined with the Nd-YAG laser treatment was called group 1 (24 cases, 24 eyes); patients who received the argon bluegreen laser combined with the krypton red laser and the Nd-YAG laser treatment was called group 2 (61 cases, 61 eyes). In comparison, the age, duration of CRVO before treatment, and visual acuity at the time of treatment was not significantly different between the two groups (P40.05). Follow-up time ranged from 6 to 36 months (average7SD of 12.279.9 months). Successful anastomosis formed in 13 out of 24 eyes (54%) in group 1 and 47 out of 61 eyes (77%) in group 2. The number of eyes with successful anastomosis was significantly different between the two groups (Po0.05). Two to four treatment sites were selected for each eye, with a mean of 2.570.7 in group 1 and 7SD of 2.470.6 in group 2. The total number of attempts is 60 in group 1 and 148 in group 2. Successful anastomosis formed in 16 out of 60 treatment sites in group 1 and 60 out of 148 in group 2.
In the 60 eyes with successful anastomosis, visual acuity improved for two or more lines in 49 eyes (82%). Visual acuity remained stable in the rest of the patients. In the 25 eyes (25 patients) where anastomosis did not form, visual acuity improved for two or more lines in six eyes (24%), decreased in nine eyes (36%), and remained unchanged in 10 eyes. The difference between the number of eyes achieving better vision or a worsening of vision between the two groups was statistically significant (Po0.01).
In all the patients with successful anastomosis, retinal haemorrhages and hard exudates started to resolve 2 weeks after treatment. Most of the retinal haemorrhages resolved 1-2 months after treatment (Figures 1 and 2 ). Hard exudates resolved more slowly. Cystoid macular oedema (CMO) resolved most slowly, it usually took more than half a year to resolve entirely. In one patient, CMO did not resolve entirely even 24 months after treatment, although retinal haemorrhages and hard exudates resolved entirely, and visual acuity improved a few months after treatment. In the 25 eyes where anastomosis did not form, retinal haemorrhages increased in five eyes (including four eyes that transformed into the ischaemic type of CRVO). Retinal haemorrhages and exudates gradually resolved in seven eyes.
Intraoperative complications occurred in most cases, including local retinal or subretinal haemorrhages in 43 eyes and slight vitreous haemorrhages in 32 eyes when the retinal vein was broken. These haemorrhages usually resolved in 4-6 weeks after treatment. Complications 
Comments
The mechanism of CRVA formation is still not very clear. The anastomosis can be induced by a high-intensity argon laser, dye yellow laser, or a combination of two lasers (argon laser and Nd-YAG laser). 1,2,3 The anastomosis also could form naturally after penetrating ocular injury. 8 Generally speaking, the anastomosis formation usually followed an injury that involved both the retina and the choroid. This was proved by an animal experiment, which showed that CRVA could only be induced when the laser intensity was high enough to break the retinal vein and the Bruch's membrane at the same time. When the laser energy was further increased, the retinal vein and the Bruch's membrane were broken at the same time, and in some specimen, when the choroidal vein was also broken, the success rate of anastomosis formation was increased prominently. 9 Combined lasers with different wavelengths may be more effective in inducing a laser injury that involves both the retina and the choroid. At first, we used two lasers in group 1, the success rate of anastomosis formation was similar to that reported in the literature (33-54%) using the original technique. 1, 2 In order to increase the success rate of anastomosis formation, we started to use three lasers in group 2 since 2000 February. The success rate of anastomosis formation in group 2 was higher. Most of the doctors in the literature used a very high-intensity argon laser alone, with power levels ranging from 0.6 to 4 W. [1] [2] [3] [4] [5] [6] Two lasers were used in some eyes to create an anastomosis (argon and YAG), 1 but the author did not compare the success rate of anastomosis formation of this group of patients with that of the other patients. When combined lasers were used as in our study, less argon laser intensity was necessary to induce anastomosis formation. In group 2, the krypton red laser was used in addition to the argon laser and the YAG laser. The krypton red laser has a longer wavelength and deeper penetration. It mainly focuses on the choroid with greater sparing of the inner retinal layers, 10 so it may be used to break the Bruch's membrane and choroidal vein more effectively than the argon laser. We think that we can induce retinal and choroidal injury at the treatment site more effectively by using the combined lasers with three different wavelengths. This may explain the higher success rate of anastomosis formation in group 2.
Recently, modifications of the technique were made in order to increase the success rate of anastomosis formation. Koizumi et al 11 transected the retinal vein in addition to making a small incision in the wall and full thickness retina. They thought that transecting the retinal vein could increase successful anastomosis formation. Leonard et al 12 reported 100% success rate of anastomosis formation by using medium-intensity, long-duration argon laser photocoagulation spots without puncturing the vein wall. They thought that puncturing the vein wall was unnecessary in inducing the anastomosis formation. These modifications of the technique were only reported in small case series and were not repeated by other doctors. One of the complications was distal vein occlusion at the treatment site, leaving a segmental area of retinal ischaemia and various neovascular and fibrous tissue proliferation.
1 Sectoral scatter laser photocoagulation was used to prevent the growth of retinal neovascularization in case distal vein occlusion occurs at the treatment site. In comparison with other studies that did not use sectoral scatter laser photocoagulation, the success rate of anastomosis formation is higher in group 2 and indicates that sectoral scatter laser photocoagulation did not interfere with the formation of anastomosis.
In one study, 1 distal vein occlusion at the treatment site occurred in 29% of 91 eyes. In another study, 3 it occurred in two out of eight cases (25%). In the above studies, usually several overlapping argon laser shots at each treatment site were applied. In comparison, distal vein occlusion at the treatment site occurred much less frequently in our study (2%). This can be explained as follows: the argon laser is haemoglobin-absorbing wavelength. When very high-intensity argon laser is used to break the whole layer of the retina and Bruch's membrane, it may cause thrombus formation and distal vein occlusion. As we used less argon laser intensity (1.5-2.4 W), there might have been less chance of distal vein occlusion. In comparison with the argon laser, the krypton red laser is poorly absorbed by haemoglobin, 10 so it may not increase the chance of thrombus formation or distal vein occlusion at the treatment sites in group 2.
The most serious complication was neovascularization at the treatment site. The occurrence rate was reported to be about 20%. [1] [2] [3] Neovascularization was usually caused by retinal ischaemia. 1 In our study, neovascular complications only developed in four eyes (5%) that transformed to the ischaemic type of CRVO without anastomosis formation. First of all, we selected patients with less degree of retinal ischaemia than that reported in other studies. 1 Patients with 5-disc diameters or less of capillary nonperfusion were included in our study, whereas in most other studies, patients with 10-disc diameters or less of capillary nonperfusion were included. [1] [2] [3] [4] [5] [6] This may contribute to the decreased occurrence of neovascular complications in our study. Second, distal vein occlusion at the treatment site occurred much less frequently in our study as described above. This may also contribute to decreased occurrence of neovascular complications in our study. Third, during the treatment, scattered argon laser usage around and distal to the treatment site may be effective in preventing the growth of retinal neovascularization in case distal vein occlusion occurred after treatment. Sectoral scatter laser could destruct the ischaemic zones caused by distal vein occlusion. This might eliminate the source of angiogenic stimulus from the ischaemic zones. In one study, 1 neovascular complications associated with distal vein occlusion occurred in almost all the cases, whereas none occurred in our study. In the two cases that transformed to the ischaemic type of CRVO, the retinal ischaemia was so widespread that sectoral scatter laser photocoagulation was not enough to prevent the development of neovascularization. Although PRP treatment was tried at the first follow-up visit, the retinal oedema and retinal haemorrhages were so serious that it prevented complete PRP. The new vessels continued to grow, because the source of angiogenic stimulus from the ischaemic zones still existed owing to incomplete PRP.
After successful anastomosis, all the patients showed improved retinal changes and most patients (82%) had an improved visual acuity. This is in agreement with most other studies. 1, 2 In the natural history report of CRVO by CVOS, 13 ischaemia developed in 34% of the 547 initially perfused eyes, whereas none occurred in our cases with successful anastomosis. This indicates that successful anastomosis may prevent the development of ischaemia.
Among the 714 eyes enrolled in the study conducted by the CVOS, 13 29% had an initial visual acuity of 20/40 or better and 28% of the eyes were worse than 20/200. After 3-year follow-up, the final visual acuity remained 20/40 or better in 28% of the cases and were worse than 20/200 in 41% of the cases. In our patients with successful anastomosis, nine eyes (15%) had an initial visual acuity of 20/40 or better and 11 eyes (18%) were worse than 20/200 (Table 1) . After successful anastomosis, 25 eyes (42%) had a final visual acuity of 20/40 or better and only four eyes (6%) were worse than 20/200 (Table 2 ). This indicates that successful anastomosis may improve the visual prognosis of the patients with nonischaemic CRVO.
Limitations of this study include its retrospective design and a relatively small number of cases. However, the number of patients in this study is larger than that in most other studies of CRVA. To our knowledge, only one retrospective study, with 91 cases, had a larger number.
